Rationale Tuberculosis remains a worldwide problem, particularly with the advent of multi-
drug resistance. Shortening therapy duration for Mycobacterium tuberculosis is a major goal …

Background A major challenge in medicine is translation of preclinical model findings to
humans, especially therapy duration. One major example is recent shorter-duration therapy …

Mycobacterium tuberculosis metabolic state affects the response to therapy. Quantifying the
effect of antimicrobials in the acid and nonreplicating metabolic phases of M. tuberculosis …

NEW TOOLS to improve the treatment and control of tuberculosis (TB) are a critical
component of any comprehensive strategy to eradicate the global TB epidemic. In particular …

Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued
humanity for centuries and has claimed numerous lives across the globe. Concerted efforts …

Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial
state affecting approximately 25% of the global population. The substantial prevalence of …

Integrated computational approaches for Mycobacterium tuberculosis (Mtb) are useful to
identify new molecules that could lead to future tuberculosis (TB) drugs. Our approach uses …

Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

Our understanding of the host‐pathogen relationship in tuberculosis (TB) can help guide
drug discovery in at least two ways. First, the recognition that host immunopathology affects …

Standard antituberculosis (anti-TB) therapy requires the use of multiple drugs for a minimum
of 6 months, with variable outcomes that are influenced by a number of microbiological …